The short answer on candidacy

Most patients asking about ChondroFiller™ are at a specific point in their knee story: physiotherapy has not resolved their symptoms, but a knee replacement feels premature or simply is not yet indicated. That gap — between 'conservative care has stalled' and 'end-stage joint disease' — is precisely where this treatment is designed to sit.

ChondroFiller™ is an injectable collagen scaffold delivered under ultrasound guidance as an outpatient procedure. It is not a surgical or keyhole operation. Once placed into a focal area of cartilage damage in the knee, the scaffold self-gels and provides a structural matrix that supports the body's own repair processes — recruiting the patient's progenitor cells to promote endogenous cartilage repair.

The broadest candidacy profile covers adults with symptomatic focal knee cartilage defects up to 6 cm², whether from a previous knee injury, sport-related trauma, or early-to-moderate degenerative wear. There is no strict upper age limit for the injection pathway. The same device is also marketed under the name Liquid Cartilage™; both names refer to the identical CE-marked Class III murine-derived Type I collagen scaffold.

If conservative care — including physiotherapy and anti-inflammatory measures — has not delivered adequate relief, and imaging confirms the right pattern of cartilage damage, the injection candidacy assessment is the logical next step.

How the scaffold works inside the knee

The scaffold itself contains no added cells — ChondroFiller™ is acellular, arriving as a pure collagen matrix that relies entirely on the patient's own biology for the biological work. Once in place, it acts as a chemotactic environment: progenitor cells from the surrounding synovium and subchondral bone migrate into the matrix, gradually differentiating into chondrocytes and producing repair tissue. Clinically, this process is described as acellular matrix-induced chondrogenesis — the scaffold provides the architecture; the patient's cells carry out the repair.

What distinguishes the injectable form from earlier surgical approaches is its top-down action. Rather than requiring a surgically prepared defect bed, the scaffold drapes across the articular surface and adheres to existing cartilage, whether the damage is focal or more diffuse. A wider or irregular wear pattern does not prevent placement — one reason the injection pathway carries no strict upper limit on defect area.

MRI imaging captures this process unfolding over time: in knee studies, MOCART scores progress from approximately 65 at four weeks to over 81 at one year, reflecting gradual scaffold maturation and increasing defect filling as the patient's own tissue builds within the matrix. That trajectory directly informs which patients are assessed as suitable — and over what timeframe realistic improvement can be expected.

The patient profile most likely to benefit

Three imaging findings, taken together, define the most suitable candidate for assessment. On weight-bearing X-ray, Kellgren-Lawrence Grade I–III — indicating mild-to-moderate loss of joint space without complete cartilage obliteration — represents the primary clinical sweet spot. MRI then maps the damage in greater detail: a focal or regionally contained chondral lesion, typically arising from a previous knee injury, sport-related trauma, or early degenerative wear, with surrounding tissue retaining enough structural integrity to support the repair process. Patients with Grade III–IV changes on X-ray are not automatically excluded; some are assessed individually as pre-replacement candidates for whom injection may extend the window before surgery becomes necessary.

Beyond imaging, the clinical history carries weight. The typical candidate has lived with knee pain and functional restriction for a meaningful period — months rather than weeks — and has already worked through a course of conservative management: physiotherapy, activity modification, anti-inflammatory measures, or prior injection therapy. That treatment history is not a formality; it establishes that symptoms are persistent and not resolvable without a more targeted intervention.

Lifestyle and mechanical factors complete the profile. Patients at or near a healthy body weight place less cyclical load through the repair site during scaffold maturation, which clinical experience associates with better integration outcomes. Joint mechanics are evaluated as prerequisites rather than optional considerations: significant ligament instability, leg malalignment exceeding five degrees, or scar-tissue restriction must be addressed before injection is undertaken — a mechanically hostile environment limits how well the scaffold can function regardless of the cartilage findings. Published series show that patients aged roughly 40 to 65 represent the majority of those treated, reflecting the combination of active lifestyle, biological repair capacity, and the stage of joint disease where the intervention adds most value — though individual assessment at consultation is what ultimately determines suitability.

Who is not suitable for this treatment

Absolute exclusions apply to several groups of patients, and these are non-negotiable. ChondroFiller™ cannot be used in anyone who is pregnant or breastfeeding, has an active infection inside the knee joint, carries a diagnosis of inflammatory arthritis — including rheumatoid arthritis, gout, or other systemic inflammatory joint disease — or has a known allergy to collagen or murine (rodent-derived) protein. None of these is addressable by sequencing or staging, and proceeding in their presence would carry unacceptable risk.

Beyond these hard stops, the scaffold is designed for joints where some viable cartilage and intact subchondral architecture remain — it cannot replace cartilage that no longer exists. The clinical signal most consultants use to step back from the injection pathway is a bone-on-bone appearance under load on a weight-bearing X-ray: when joint space is completely, or near-completely, obliterated at rest and under body weight, the environment may not support meaningful scaffold function. The precise Kellgren-Lawrence grade at which this threshold falls has not been definitively published for the injection-only pathway; that determination is made at consultation following imaging review, not from a fixed published cut-off. Patients in this position are not without options — a consultant can advise whether a different joint-preservation approach, or planning for joint replacement, better matches their findings.

Where significant ligament laxity or malalignment is present and can be corrected, it must be before any injection is undertaken. If those structural problems are not correctable, the injection is unlikely to perform as intended.

Patients who have already agreed to and are awaiting joint replacement surgery should raise the question of timing directly with their treating consultant; whether an injection at that stage adds value or conflicts with the planned procedure is a decision that requires individual clinical input.

How candidacy is assessed before treatment

The assessment appointment is structured around three sequential steps before any treatment decision is reached.

MRI comes first. The scan maps the cartilage defect in three dimensions — its location, depth, and the condition of the surrounding tissue — and is the direct basis for dosing. One, two, or three units of the collagen scaffold are required depending on the size and distribution of damage identified on imaging; without the scan, dosing cannot be determined and treatment cannot safely proceed. Where available, AI-assisted cartilage and meniscus segmentation — provided through onMRI™, a proprietary MRI analysis tool used within the MSK Doctors group — supports more precise defect characterisation, including T2 mapping of cartilage quality, beyond what standard radiological reporting typically delivers.

A standing, weight-bearing X-ray follows. Non-weight-bearing imaging can understate the degree of joint space narrowing; a standing film under load provides a more accurate Kellgren-Lawrence grade and reveals how joint mechanics behave under the forces the patient actually experiences day to day. That grade — and what it shows about remaining joint space and alignment — informs both candidacy and the conversation about whether any mechanical problem must be corrected first.

Clinical scoring at assessment establishes a validated functional baseline. VAS scores capture current pain intensity; WOMAC records function, stiffness, and activity limitation. Both provide a pre-treatment reference against which improvement can be measured objectively at follow-up. In some assessments, movement quality is evaluated using MAI Motion®, a proprietary biomechanical analysis platform used across the MSK Doctors group, which produces objective gait and movement biomarkers independent of patient self-report.

No imaging review, no treatment. Any provider willing to quote or proceed without first reviewing MRI and weight-bearing X-ray is not following the required clinical protocol.

What the clinical evidence shows for suitable candidates

Numbers help here. In knee-specific studies, patients treated with the ChondroFiller® collagen scaffold show a mean IKDC score improvement of approximately 30 points at 12 months — a threshold that comfortably exceeds the minimum clinically important difference for this outcome measure, established at 16.7 points. In practical terms, a 30-point gain corresponds to a meaningful, patient-felt shift in knee function: returning to activities that had become restricted, rather than a marginal statistical change on a questionnaire. The Jerosch et al. prospective post-market clinical follow-up study reported a mean improvement of 32.4 points, sustained at three-year follow-up, with patients reaching a functional IKDC score of 80.

MRI-based structural evidence supports those functional gains. MOCART scores — a validated imaging measure of defect fill and scaffold integration — range from 81.6 to 84.3 in treated knee patients, indicating that more than 80% of the defect area is filled and that the scaffold has integrated with surrounding native cartilage. Progression from a MOCART score of 65.3 at four weeks to 81.6 at one year reflects the ongoing maturation of the repair tissue over the post-treatment period rather than an immediate structural effect.

The safety profile is consistent across studies: complication rates are approximately 0%, and the reoperation rate sits at 3–8% at medium-term follow-up — comparing favourably with the reoperation rates of up to 41% reported for microfracture.

What the longer-term picture looks like

Cross-joint evidence — encompassing the knee alongside other joints — is consistent with 70–85% of patients achieving meaningful symptom relief at three to five years. That figure should be read carefully: knee-specific, long-term RCT data beyond three years remains limited, and no published head-to-head trial has directly compared the injection pathway against MACI specifically in the knee. The available evidence is consistent with durable benefit; it does not yet constitute proof from a large, knee-only randomised trial.

These outcomes reflect performance in patients whose assessment findings matched the candidacy criteria covered in the sections above — confirmed cartilage damage on MRI, a mechanically sound and properly aligned joint, and absence of inflammatory or end-stage disease. Patients whose imaging and clinical profile place them squarely in that group are the ones in whom published outcomes were achieved.